Lupin Limited will engage with the investment community through a series of analyst and institutional investor meets scheduled for early June 2026. The company is set to attend three major conferences, providing a platform for management to discuss business performance and strategy with market participants.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Amit Kumar Gupta, Company Secretary & Compliance Officer, confirmed the participation schedule in a filing to the exchanges.

Schedule of Events

The following table outlines the confirmed dates and details for the upcoming investor interactions:

Key Disclosures

The company noted that the dates for these events are subject to change due to exigencies on the part of the company or the event organizers. Any presentations made during these meets will align with information already available on the company's website and the stock exchanges.

Lupin Limited's registered office is located at 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India.

Lupin has received approval from China's National Medical Products Administration for its Oseltamivir Phosphate Oral Suspension, marking the company's first product entry into the Chinese market. The approval was granted for an Abbreviated New Drug Application in partnership with Yabao Pharmaceuticals, a leader in China's pediatric medicine market. This milestone represents a significant step in Lupin's global expansion strategy.

Approval Details

The following table summarizes the key details of this regulatory milestone:

Significance of the Approval

Oseltamivir Phosphate is an antiviral agent indicated for the treatment of influenza A and B in patients two weeks of age and older, and for prevention in individuals one year of age and older. The oral suspension form is particularly relevant for pediatric and other patient populations requiring liquid formulations. Securing approval in China, one of the largest pharmaceutical markets globally, allows Lupin to expand access to high-quality, affordable medicines.

Fabrice Egros, President - Corporate Development, Lupin, stated that the approval is a strategic step into one of the world's largest pharmaceutical markets. He emphasized the shared commitment to expanding access to therapies, particularly in pediatric care. Wei Ren, President of Yabao, noted that the approval reinforces Yabao's dedication to quality pediatric medicines and showcases the strong collaboration between the two entities.